Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS
Blood Journal · 13.11.2026
DOI: 10.1182/blood.2026035348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Journal, online erschienen am 13.11.2026. Verfasst von Andrew M Brunner und 59 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital, Boston, Massachusetts, United States.
Abstract (Originalsprache)
Variability in how clinical trial elements are reported can hinder accurate interpretation and comparison of trial results. Here, we systematically analyzed published manuscripts of therapeutic clinical trials in myelodysplastic syndromes/neoplasms (MDS) focusing on how key data elements were reported and made recommendations on how to improve this reporting. We included peer-reviewed full text manuscripts that reported results of clinical trials in MDS and were published between January 1, 2015 to December 31, 2024. We analyzed the presence or absence of several pre-determined key reporting elements and then synthesized these data to evaluate for consistency across manuscripts. We identified substantial variability in descriptions of patient characteristics, as well as the definitions used for response criteria. For example, baseline ANC was reported in only 16% of lower-risk MDS studies and 23% of higher-risk MDS studies, while baseline bone marrow blast percentage was reported in only 55% of higher-risk MDS manuscripts. In addition, response endpoints lacked standardization, with six unique definitions of RBC transfusion independence identified in lower-risk MDS trials and seven different definitions of overall response rate identified in higher-risk MDS trials. Informed by the results of this analysis, we then performed a modified-Delphi process for members of the International Consortium for MDS (icMDS) to develop consensus-based recommendations for consistent and accurate reporting of MDS clinical trial results. We advocate that these recommendations serve as benchmarks and templates for clinical trial reporting in MDS to improve interpretability and comparison of results.
Autor:innen und Institutionen
- Massachusetts General Hospital, Boston, Massachusetts, United States.
- NYU Langone, Brooklyn, New York, United States.
- The Ohio State University, Columbus, Ohio, United States.
- Yale School of Medicine University, New Haven, Connecticut, United States.
- Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States.
- The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States.
ORCID-Profile: Kelly Pugh, Jan Philipp Bewersdorf, Uma Borate, Mikkael A Sekeres, Andrew H Wei, Gail J Roboz, Sanam Loghavi, Robert P Hasserjian, David A Sallman, Christopher S Hourigan, Matteo Giovanni Della Porta, Richard F Little, Valeria Santini, Fabio Efficace, Justin Taylor, Tae Kon Kim, Stephanie Halene, Rami S Komrokji, Elizabeth A Griffiths, Peter L Greenberg, Rafael Bejar, Mrinal M Patnaik, Hetty E Carraway, Jacqueline Boultwood, Naval G Daver, Jane E Churpek, Shahram Kordasti, Adrian Mosquera Orgueira, Francesc Sole, Arjan A van de Loosdrecht, Thomas Cluzeau, Lionel Adès, Yazan F Madanat, R Coleman Lindsley
Zitieren
APA
Brunner, A. M., Getz, T. M., Pugh, K., Bewersdorf, J. P., Kewan, T., Borate, U., DeZern, A. E., Platzbecker, U., Sekeres, M. A., Wei, A. H., Buckstein, R. J., Roboz, G. J., Savona, M. R., Loghavi, S., Hasserjian, R. P., Fenaux, P., Sallman, D. A., Hourigan, C. S., Della Porta, M. G., …, & Lindsley, R. C. (2026). Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS. Blood Journal. https://doi.org/10.1182/blood.2026035348
Vancouver
Brunner AM, Getz TM, Pugh K, Bewersdorf JP, Kewan T, Borate U, et al. Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS. Blood Journal. 2026. doi:10.1182/blood.2026035348
BibTeX
@article{Brunner2026,
author = {Brunner, Andrew M and Getz, Ted M and Pugh, Kelly and Bewersdorf, Jan Philipp and Kewan, Tariq and Borate, Uma and DeZern, Amy E and Platzbecker, Uwe and Sekeres, Mikkael A and Wei, Andrew H and Buckstein, Rena J and Roboz, Gail J and Savona, Michael R and Loghavi, Sanam and Hasserjian, Robert P and Fenaux, Pierre and Sallman, David A and Hourigan, Christopher S and Della Porta, Matteo Giovanni and Nimer, Stephen D and Little, Richard F and Santini, Valeria and Efficace, Fabio and Taylor, Justin and Odenike, Olatoyosi and Kim, Tae Kon and Halene, Stephanie and Komrokji, Rami S and Griffiths, Elizabeth A and Greenberg, Peter L and Xu, Mina L and Xie, Zhuoer and Bejar, Rafael and Sanz, Guillermo and Patnaik, Mrinal M and Figueroa, Maria E and Carraway, Hetty E and Abdel-Wahab, Omar and Starczynowski, Daniel T and Padron, Eric and Boultwood, Jacqueline and Gore, Steven D and Daver, Naval G and Churpek, Jane E and Bennett, John M and List, Alan F and Kordasti, Shahram and Mosquera Orgueira, Adrian and Metzeler, Klaus H and Sole, Francesc and Pleyer, Lisa and van de Loosdrecht, Arjan A and Cluzeau, Thomas and Steensma, David Peter and Mufti, Ghulam J and Adès, Lionel and Sebert, Marie and Platzbecker, Anne Sophie and Madanat, Yazan F and Lindsley, R Coleman},
title = {Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS},
journal = {Blood Journal},
year = {2026},
doi = {10.1182/blood.2026035348}
}
EUVIMED